Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 146 from CHF 136 and keeps an Overweight rating on the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDGF:
- Medacta Group SA Reports Strong 2024 Financial Growth
- Medacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic Solutions
- Medacta Group SA: Strong Financial Performance and Growth Potential Justify Buy Rating
- Medacta Group price target raised to CHF 160 from CHF 150 at Berenberg
- Medacta Group price target raised to CHF 136 from CHF 135 at Morgan Stanley